Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,252
  • Shares Outstanding, K 73,543
  • Annual Sales, $ 65,490 K
  • Annual Income, $ 8,310 K
  • EBIT $ -15 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.67
  • Price/Sales 1.30
  • Price/Cash Flow 8.50
  • Price/Book 2.98

Options Overview Details

View History
  • Implied Volatility 250.20% ( +3.94%)
  • Historical Volatility 60.50%
  • IV Percentile 88%
  • IV Rank 41.18%
  • IV High 590.01% on 04/19/24
  • IV Low 12.33% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 4,375
  • Open Int (30-Day) 4,160

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.06
  • Number of Estimates 1
  • High Estimate 0.06
  • Low Estimate 0.06
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +250.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +30.69%
on 10/22/24
1.3600 -2.94%
on 11/04/24
+0.2400 (+22.22%)
since 10/11/24
3-Month
0.8214 +60.70%
on 08/14/24
1.3600 -2.94%
on 11/04/24
+0.2700 (+25.71%)
since 08/12/24
52-Week
0.8214 +60.70%
on 08/14/24
1.9000 -30.53%
on 12/26/23
-0.0200 (-1.49%)
since 11/10/23

Most Recent Stories

More News
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 8.48 (-6.19%)
PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics Issues Letter to Stockholders

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics set to join Russell 3000® Index

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.3200 (+10.00%)
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

PLX : 1.3200 (+10.00%)
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.3200 (+10.00%)
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.3200 (+10.00%)

Business Summary

Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.

See More

Key Turning Points

3rd Resistance Point 1.5133
2nd Resistance Point 1.4267
1st Resistance Point 1.3733
Last Price 1.3200
1st Support Level 1.2333
2nd Support Level 1.1467
3rd Support Level 1.0933

See More

52-Week High 1.9000
Fibonacci 61.8% 1.4880
Fibonacci 50% 1.3607
Last Price 1.3200
Fibonacci 38.2% 1.2334
52-Week Low 0.8214

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar